Doctors responding to an online MedPage Today survey overwhelmingly rejected the idea of writing new prescriptions for patients with diabetes for rosiglitazone (Avandia).
Seventy-two percent of more than 200 respondents voted no to the question of whether they would start patients on rosiglitazone in view of the published report linking the drug to a 43% increase in the relative risk of myocardial infarction among those with diabetes.
The meta-analysis in the New England Journal of Medicine was conducted by Steven Nissen, M.D., of the Cleveland Clinic, and colleagues.
No comments:
Post a Comment